Publication
525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
V. Makker, N. Colombo, A. Casado Herraez, B.J. Monk, H. Mackay, A.D. Santin, D.S. Miller, R.G. Moore, S.E. Baron-Hay, I.L. Ray-Coquard, R. Shapira-Frommer, K. Ushijima, K. Yonemori, Y.M. Kim, E.M. Guerra Alia, U.A. Sanli, J. Huang, J. McKenzie, G. Barresi, D. Lorusso
Annals of Oncology, September 2022, Elsevier
DOI: 10.1016/j.annonc.2022.07.653